Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Regulation of tNOX expression through the ROS-p53-POU3F2 axis contributes to cellular responses against oxaliplatin in human colon cancer cells

Fig. 6

a, HCT116 cells were treated with oxaliplatin or ddH2O for 24 h, and tNOX mRNA levels were determined by RT-PCR. The presented results represent three independent experiments (**p < 0.01, ***p < 0.001 for cells treated with oxaliplatin vs. controls). b, p53-wild-type cells were co-transfected with a reporter construct and a POU3F2 expression vector, and luciferase activities were determined. The presented values (mean ± SD) represent three independent experiments performed in at least triplicate (**p < 0.01 for experimental group vs. control). c, p53-wild-type cells were transfected with the POU3F2 expression vector for 24 h and then exposed to oxaliplatin for an additional 24 h. Cell lysates were separated by SDS-PAGE and analyzed by Western blotting. β-Actin was used as an internal control. Representative images are shown. The percentage of apoptotic cells was also determined by flow cytometry; the presented values (mean ± SEs) represent at least three independent experiments (***p < 0.001 for treatments vs. controls). d, p53-null cells were transfected with the shPOU3F2 knockdown vector for 24 h and then exposed to oxaliplatin for an additional 24 h. Cell lysates were separated by SDS-PAGE and analyzed by Western blotting. β-Actin was used as an internal control. Representative images are shown. The percentage of apoptotic cells was also determined by flow cytometry; the presented values (mean ± SEs) represent at least three independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001 for treatments vs. controls)

Back to article page